Andrew Hirsch serves as our President and a member of our Board of Directors. He is also our incoming Chief Executive Officer. Previously, Andrew served as Chief Financial Officer at Agios Pharmaceuticals, Inc. from September 2016 to September 2020, including as head of corporate development beginning March 2018. Andrew has more than 20 years of experience in a range of strategic and operating roles in the biotechnology sector, previously serving as President and Chief Executive Officer of BIND Therapeutics, Inc. from March 2015 until August 2016. Prior to being named President and Chief Executive Officer, Andrew held several other leadership positions at BIND, including Chief Operating Officer from February 2014 to March 2015, and Chief Financial Officer from July 2012 to March 2015. Prior to joining BIND, Andrew was Chief Financial Officer at Avila Therapeutics, Inc. from June 2011 until its acquisition by Celgene Corporation in March 2012. From 2002 to 2011, Andrew held roles of increasing responsibility at Biogen Inc., including Vice President of Corporate Strategy and M&A and program executive for the Tecfidera development team. Since May 2017, Andrew has served on the board of directors of Editas Medicine, Inc. (Nasdaq: EDIT) where he is also the chair of the audit committee. Andrew holds an M.B.A. from the Tuck School at Dartmouth College and a B.A. in Economics from the University of Pennsylvania.